Heat Biologics (HTBX) Posts Q2 Loss of 44c/Share

Heat Biologics (NASDAQ: HTBX) reported Q2 EPS of ($0.44), $0.04 worse than the analyst estimate of ($0.40).

For earnings history and earnings-related data on Heat Biologics (HTBX) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• Freeport Q3 2026 copper output meets targets; gold sales deferred
• Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'